Current treatment algorithm: diffuse large B cell lymphoma
The article describes a risk‑adapted initial therapy that includes R‑CHOP for most patients and Pola‑R‑CHP for ABC‑subtype DLBCL.
Diffuse large B-cell lymphoma (DLBCL) ...
Defining the optimal frontline regimen for DLBCL reduces relapse and improves survival.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024)
- Mantle‑Cell Lymphoma (MCL)
- Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)
- Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report
- Loncastuximab in high‑risk and heavily pre‑treated relapsed/refractory diffuse large B‑cell lymphoma: a real‑world analysis from 21 US centers